Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
Sekisui announces the decision to invest £14.4 Million in its biopharma CDMO business aimed at cGMP microbial capacity expansion at the existing site in Maidstone, Kent to be completed by the second...
Sekisui Diagnostics Enzyme business announces the completion of a new BioProcess Innovation Centre at the site in Maidstone, Kent by the end of 2019, following a $1.9 million investment. This...
Today Sekisui Diagnostics announces the launch of the Silaris™ Influenza A&B Test. The Silaris™ test was developed by Mesa Biotech and utilizes an affordable, polymerase chain reaction (PCR) testing...
-- Sekisui Diagnostics becomes exclusive distributor for Mesa Biotech products in the U.S. and Canada -- Strategic alliance expands Sekisui Diagnostics' portfolio and facilitates entry into the...
Sekisui Diagnostics has significantly expanded its point of care (POC) diagnostics product line through a recent partnership agreement with Qualigen, Inc. Sekisui Diagnostics is now the exclusive...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.